血液系统恶性肿瘤中发热性中性粒细胞减少症的治疗与预防：一项批判性综述与更新
Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update.
作者信息
Villafuerte-Gutierrez Paola, Villalon Lucia, Losa Juan E, Henriquez-Camacho Cesar
机构信息
Hospital Universitario Torrejón de Ardoz, Servicio de Hematología, Calle Mateo Inurria, 28850 Madrid, Spain.
Hospital Universitario Fundación Alcorcón, Servicio de Hematología, Calle Budapest 1, 28922 Madrid, Spain.
出版信息
Adv Hematol. 2014;2014:986938. doi: 10.1155/2014/986938. Epub 2014 Nov 27.
Abstract
Febrile neutropenia is one of the most serious complications in patients with haematological malignancies and chemotherapy. A prompt identification of infection and empirical antibiotic therapy can prolong survival. This paper reviews the guidelines about febrile neutropenia in the setting of hematologic malignancies, providing an overview of the definition of fever and neutropenia, and categories of risk assessment, management of infections, and prophylaxis.
摘要
发热性中性粒细胞减少是血液系统恶性肿瘤患者和接受化疗患者最严重的并发症之一。及时识别感染并进行经验性抗生素治疗可延长生存期。本文综述了血液系统恶性肿瘤患者发热性中性粒细胞减少的相关指南，概述了发热和中性粒细胞减少的定义、风险评估类别、感染管理及预防措施。
相似文献
1
Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update.
Adv Hematol. 2014;2014:986938. doi: 10.1155/2014/986938. Epub 2014 Nov 27.
2
Febrile neutropenia in hematologic malignancies.
Curr Hematol Malig Rep. 2013 Dec;8(4):370-8. doi: 10.1007/s11899-013-0171-4.
3
Febrile neutropenia in haematological malignancies.
J Postgrad Med. 2005;51 Suppl 1:S42-8.
4
Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia.
Cochrane Database Syst Rev. 2016 Apr 24;4(4):CD006247. doi: 10.1002/14651858.CD006247.pub3.
5
Prophylaxis and treatment of bacterial infections: do we need new strategies?
Rev Clin Exp Hematol. 2005 Dec;9(2):E4.
6
Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia.
Cochrane Database Syst Rev. 2012 Sep 12(9):CD006247. doi: 10.1002/14651858.CD006247.pub2.
7
[Evaluation of antibiotic prophylaxis in neutropenic patients with hematologic malignancies].
Schweiz Med Wochenschr. 2000 Dec 2;130(48):1837-44.
8
A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.
Scand J Infect Dis. 2004;36(8):593-600. doi: 10.1080/00365540410017590.
9
Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial.
Lancet Haematol. 2017 Dec;4(12):e573-e583. doi: 10.1016/S2352-3026(17)30211-9. Epub 2017 Nov 15.
10
Review of the value of colony stimulating factors for prophylaxis of febrile neutropenic episodes in adult patients treated for haematological malignancies.
Br J Haematol. 2007 Jul;138(2):146-52. doi: 10.1111/j.1365-2141.2007.06653.x.
引用本文的文献
1
Does the Timing of Response Impact the Outcome of Relapsed/Refractory Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents? A Proof of Concept from a Monocentric Observational Study.
J Clin Med. 2025 Aug 7;14(15):5586. doi: 10.3390/jcm14155586.
2
High-Dose Methotrexate Usage Without Drug-Level Monitoring in Advanced Pediatric Mature B-Cell Non-Hodgkin Lymphoma in a Resource-Limited Setting in Malawi.
JCO Glob Oncol. 2025 Mar;11:e2400591. doi: 10.1200/GO-24-00591. Epub 2025 Mar 28.
3
Ceftazidime-avibactam for the treatment of febrile neutropenia in HSCT recipients and acute leukemia patients post induction chemotherapy.
Sci Rep. 2024 Dec 28;14(1):31322. doi: 10.1038/s41598-024-82795-9.
4
Efficacy and Safety of Oral and IV Levonadifloxacin Therapy in Management of Bacterial Infections: Findings of a Prospective, Observational, Multi-center, Post-marketing Surveillance Study.
Cureus. 2024 Feb 28;16(2):e55178. doi: 10.7759/cureus.55178. eCollection 2024 Feb.
5
The Use of Granulocyte Colony-Stimulating Factor as Primary Prophylaxis in Patients Undergoing Chemotherapy: An Experience of Moroccan Oncologists.
Cureus. 2024 Feb 19;16(2):e54482. doi: 10.7759/cureus.54482. eCollection 2024 Feb.
6
The efficacy of L. in reducing neutrophil recovery time in childhood cancer with febrile neutropenia: a randomized, double-blind, placebo-controlled trial.
Am J Blood Res. 2023 Oct 15;13(5):143-151. eCollection 2023.
7
Microbiological Spectrum of Neutropenic Sepsis in Cancer Patients Admitted to a Tertiary Health Care Centre.
Cureus. 2023 Aug 22;15(8):e43898. doi: 10.7759/cureus.43898. eCollection 2023 Aug.
8
Classification of Chemotherapy-Induced Febrile Neutropenic Episodes Into One of the Three Febrile Neutropenic Syndromes.
Cureus. 2023 Aug 2;15(8):e42843. doi: 10.7759/cureus.42843. eCollection 2023 Aug.
9
Antimicrobial Stewardship Program for Patients in the Hematological Department Receiving Carbapenem Therapy: A Single-Center and Interrupted Time Series Analysis.
Antibiotics (Basel). 2023 Feb 2;12(2):302. doi: 10.3390/antibiotics12020302.
10
Alarming Antibiotic Resistance in Pediatric Oncology Patients: A Three-Year Prospective Cohort Study from Oman.
Infect Drug Resist. 2022 Jul 25;15:3939-3947. doi: 10.2147/IDR.S369909. eCollection 2022.
本文引用的文献
1
Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact.
Curr Opin Infect Dis. 2014 Apr;27(2):200-10. doi: 10.1097/QCO.0000000000000038.
2
Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011).
Haematologica. 2013 Dec;98(12):1836-47. doi: 10.3324/haematol.2013.091330.
3
Evidence-based approach to treatment of febrile neutropenia in hematologic malignancies.
Hematology Am Soc Hematol Educ Program. 2013;2013:414-22. doi: 10.1182/asheducation-2013.1.414.
4
Epidemiology of bloodstream infections in patients with acute myeloid leukemia undergoing levofloxacin prophylaxis.
BMC Infect Dis. 2013 Dec 1;13:563. doi: 10.1186/1471-2334-13-563.
5
Antifungal pre-emptive strategy for high-risk neutropenic patients: why the story is still ongoing.
Clin Microbiol Infect. 2014 Jun;20 Suppl 6:27-35. doi: 10.1111/1469-0691.12428. Epub 2014 Jan 28.
6
Febrile neutropenia in hematologic malignancies.
Curr Hematol Malig Rep. 2013 Dec;8(4):370-8. doi: 10.1007/s11899-013-0171-4.
7
Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia.
Cochrane Database Syst Rev. 2013 Jun 29;2013(6):CD003038. doi: 10.1002/14651858.CD003038.pub2.
8
Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.
Clin Pharmacokinet. 2013 Oct;52(10):869-83. doi: 10.1007/s40262-013-0086-1.
9
Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial.
Lancet Infect Dis. 2013 Jun;13(6):519-28. doi: 10.1016/S1473-3099(13)70076-8. Epub 2013 Apr 30.
10
Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectious diseases group trial XV.
J Clin Oncol. 2013 Mar 20;31(9):1149-56. doi: 10.1200/JCO.2012.45.8109. Epub 2013 Jan 28.
Zotero 插件